Davis Capital Management Makes New Investment in Kenvue Inc. (NYSE:KVUE)

Davis Capital Management purchased a new position in Kenvue Inc. (NYSE:KVUEFree Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 23,531 shares of the company’s stock, valued at approximately $500,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Clearstead Advisors LLC purchased a new position in shares of Kenvue during the 3rd quarter valued at approximately $25,000. Planned Solutions Inc. purchased a new position in shares of Kenvue during the 4th quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Kenvue during the 4th quarter valued at approximately $28,000. CVA Family Office LLC purchased a new position in shares of Kenvue during the 4th quarter valued at approximately $32,000. Finally, Pinnacle Bancorp Inc. boosted its stake in shares of Kenvue by 51.3% during the 4th quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after buying an additional 526 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE traded down $0.27 during trading hours on Wednesday, reaching $18.52. 21,747,347 shares of the company’s stock traded hands, compared to its average volume of 18,611,194. The firm has a market capitalization of $35.46 billion and a price-to-earnings ratio of 23.74. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. Kenvue Inc. has a twelve month low of $17.75 and a twelve month high of $26.74. The business’s fifty day simple moving average is $19.33 and its two-hundred day simple moving average is $20.08.

Kenvue (NYSE:KVUEGet Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The business had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $3.79 billion. The business’s quarterly revenue was down 24.9% compared to the same quarter last year. Analysts predict that Kenvue Inc. will post 1.17 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were given a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.32%. Kenvue’s dividend payout ratio (DPR) is 102.56%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. HSBC increased their target price on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. The Goldman Sachs Group started coverage on Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Citigroup reissued a “neutral” rating and set a $21.00 price target on shares of Kenvue in a research report on Tuesday, May 28th. William Blair began coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. Finally, Sanford C. Bernstein began coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $23.09.

Get Our Latest Analysis on KVUE

Kenvue Company Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Read More

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.